Overview: NGS Parkinson's Dementia Alzheimer's Sequencing TestIntroduction: The NGS Parkinson's Dementia Alzheimer's Sequencing Test sequences genes to diagnose neurodegenerative disorders, causing memory loss or tremors. Following 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected Parkinson's, dementia, or Alzheimer's disease.
Other Names: PDA NGS Assay, Neurodegenerative Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Neurodegenerative sequencing began in the 1990s with Alzheimer's and Parkinson's research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose Parkinson's, dementia, or Alzheimer's, guides treatment, and evaluates patients with memory loss or tremors.
Test Parameters: 1. PDA Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of memory loss, tremors, or neurodegenerative symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document memory loss, tremors, confusion, or family history of neurodegenerative disorders. Include current medications, especially cognitive enhancers or levodopa.
Consent: Written consent required, detailing the tests purpose, neurodegenerative disorder implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze PDA genes (e.g., APP, LRRK2). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for neurodegenerative diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm neurodegenerative disorders, guiding supportive care or genetic counseling. Negative results may require cognitive testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Cognitive testing, brain MRI, or CSF analysis to confirm neurodegenerative diagnosis.
Test Limitations: Not all neurodegenerative cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Dementia Guidelines, 2023; Neurology, McKhann GM, 2022.
